Pigment Found in Chamomile, Parsley Kills Mesothelioma Cells

A yellowish pigment common to parsley, celery, chamomile tea, oranges and grapefruit may be the latest treatment for mesothelioma cancer, a new study shows. While numerous studies have demonstrated the anti-cancer and antioxidant properties of apigenin (API), the natural pigment found in these plants and vegetables, researchers recently tested it against malignant mesothelioma cells. Doctors at the University of Rome evaluated the anti-tumor activities of API in mice injected with mesothelioma cells. API inhibited malignant mesothelioma (MM) cell survival and activated cell death, known as apoptosis. Mice treated with API survived nearly twice as long as the control mice, underlining the compound’s potential for future research and clinical trials. “We demonstrated for the first time that API treatment was able to inhibit the growth of MM cell lines in vivo,” lead researcher Dr. Laura Masuelli wrote in the study. “Overall, we demonstrated that Apigenin inhibited in vitro and in vivo malignant mesothelioma cells growth by targeting different signaling pathways and inducing apoptosis.” Apigenin Lessened Fluid Buildup in Mice Lab mice implanted with MM cells experienced abnormal fluid buildup in their abdominal cavity. Injecting API directly into the abdomen (intraperitoneal injections) improved the condition and increased the median survival of the mice. Peritoneal mesothelioma is the second-most-common type of the asbestos-related cancer. Tu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: apigenin benefits apigenin for cancer apigenin for mesothelioma new mesothelioma treatment Source Type: news

Related Links:

Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Advanced Solid Tumors;   MSI-H/dMMR Tumors;   Cutaneous Squamous Cell Carcinoma;   Urothelial Carcinoma, HCC;   Cervical Cancer;   Esophageal Squamous Cell Carcinoma;   Merkel Cell Carcinoma, Small-cell Lung Cancer;   Mesothelioma;   PD-L1 Amplified Tumor (9p24.1);   Nasopharyngeal Carcinoma;   Cyclin-dependent Kinase 12 Mutated Tumors;   Basal Cell Carcinoma (Unresectable or Metastatic);   Sarcoma...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Rodent models of malignant mesothelioma help facilitate the understanding of the biology of this highly lethal cancer and to develop and test new interventions. Introducing the same genetic lesions as found in human mesothelioma in mice results in tumors that show close resemblance with the human disease counterpart. This includes the extensive inflammatory responses that characterize human malignant mesothelioma. The relatively fast development of mesothelioma in mice when the appropriate combination of lesions is introduced, with or without exposure to asbestos, make the autochthonous models particularly useful for testi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The pPCI strongly differs from the sPCI for patients undergoing CRS for peritoneal disease and may provide a more accurate evaluation of the peritoneal disease extent. Further studies are needed to determine its prognostic value compared with sPCI, and consensus guidelines are needed for calculating it. PMID: 32040698 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
ml;ksel Godderis Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers of cancer and asbestos-related diseases show encouraging results. The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. A systematic review was conducted on MEDLINE (PubMed), EMBASE and Web of Science databases to identify relevant studies. Quality assessment was done by the Newcastle–Ottawa...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research
We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up 99mTc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Our case report raises the association between prostate cancer patients treated with externa...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
microRNAs (miRNAs) are an important class of non-coding RNA that post-transcriptionally regulate the expression of most protein-coding genes. Their aberrant expression in tumors contributes to each of the hallmarks of cancer. In malignant pleural mesothelioma (MPM), in common with other tumor types, changes in miRNA expression are characterized by a global downregulation, although elevated levels of some miRNAs are also found. While an increasing number of miRNAs exhibit altered expression in MPM, relatively few have been functionally characterized. Of a growing number with tumor suppressor activity in vitro, miR-16, miR-1...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Antidoxidants | Asbestosis | Cancer | Cancer & Oncology | Chamomile | Chemistry | Chemotherapy | Clinical Trials | Environmental Health | Gene Therapy | Genetics | Grapefruit | Immunotherapy | Mesothelioma | Oranges | Study | Transplants | Vegetables